+ The results presented in this section were obtained by the Cuban laboratories LABIOFAM over 16 years of research, when they still offered ESCOZUL to patients with cancer. Today they don´t work in that way, now they market a homeopathic version called VIDATOX that does not has the properties here described and has been registered only as an analgesic (pain killer).
+ ESCOZUL has three fundamental properties demonstrated both preclinical and by the medical evidence. It is a cancer drug, analgesic and anti-inflammatory. It has been released to the public because the results obtained with cancer patients are really promising and does not cause side effects.
+ Currently, the research on its therapeutic properties is out of the scope of the Cuban government since they have decided to market a homeopathic version only has analgesic properties.
+ All research results on ESCOZUL have been reported in forums and scientific events. All the research relate to the traditional concentrated formula, not homeopathic formula.
+ The antiproliferative effect of the ESCOZUL has been clearly manifested in the experimental tumor cell lines. This means that somehow the ESCOZUL stops the cellular growth of the tumor. The experiments performed in vitro and in mice give to similar results.
+ In the Cuban state institutions attended each month over 2000 cancer patients who taked the ESCOZUL. Among the most significant cases are 187 patients who were terminally ill or in very advanced stages of the disease when they started taking the ESCOZUL and have survived for over 8 years with very good quality of life. Currently all patients who want ESCOZUL, seek for Cuba's independent producers who have been serving more than 50 000 patients for more than 20 years.
+ According to researches, 90% of patients have shown improvement in their quality of life after 2 to 3 months of starting the treatment.
|Research on ESCOZUL|
+ Until today, there is a significant amount of experimental results on the pharmacological activity of R. junceus scorpion venom. A variety of preclinical models confirm the great potential of the cuban scorpion venom as an adjuvant treatment for neoplastic diseases. Next we talk about it.
Most patients treated with the concentrated drug present breast (23.44%), prostate (17.86%), lung (8.87%), colon (8.72%) and brain cancer (8.21%). There is a large registry of the positive effects of ESCOZUL in cancer patients. More than 25.000 persons have reported an improvement after having been treated with ESCOZUL, even people to whom conventional therapy had not offered any improvement. From a clinical point of view, 90% of the patients have shown an improvement in their quality of life 2 or 3 months after starting the treatment, resulting in returning or improvement of appetite, decreased inflammation and significant decrease in pain, which allows the patient to the return to normal life.
+Treatment effects are manifested graduallly and depend on the venom concentration that is applied according to the patient's health status. Some indicators that the medicine is working include: decrease of pain and the reappearance of appetite and sleep, all what is a significant improvement in the quality of life. After some time of treatment it is observed a decrease in the metabolic activity of the tumor and decreases of tumor markers, which shows the antiproliferative activity of the drug. All these effects lead to the lengthening of life.
Evaluation of the toxic effects of venom
ESCOZUL does not cause any toxic side effect when taken orally. Experiments were made upon mice which were given different doses of ESCOZUL (0 mg/Kg, 5 mg/Kg, 50 mg/Kg y 300 mg/Kg) orally during 14 days. During this time, the mice showed different clinical signs such as: motor function, reflex, convulsions, salivation, sedation, somnolence, skin condition, mucosa, eyes and other organs. It was found that there was no mortality, weight loss or alteration of the internal organs. On the other hand it was observed sedation, a light locomotion slow down and a reflex reduction. ESCOZUL is totally safe for oral administration.
Evaluation of the analgesic activity of the blue scorpion venom (pain killer).
Yes, the ESCOZUL is a pain killer. The graphic shows the results of an experimental model of chemical analgesia. Six groups of laboratory mice subjected to different concentrations of ESCOZUL were examined, a control (+) group subjected to ASA and a control (-) group without any analgesic. The mice were induced pain by injecting acetic acid into them after which the specialists counted the number of contortions the mice suffered in a period of 10 minutes. The number of contortions is a pain indicator. The different letters inside the bars indicate significant statistical differences in the number of contortions between treatments. On the contrary, the treatments with equal letters indicate there are no differences between them. Thus, it can be observed that ESCOZUL has analgesic activity and that there are no differences between the treatment effects with ASA, 5, 10, 15, 20 and 50 mg/Kg of ESCOZUL. The graphic shows the inhibition percentage of the contortions for each treatment. It can be seen in the graphic that the treatments with high concentrations of ESCOZUL can inhibit up to 55% of pain. This experiment with mice could explain why cancer patients who are treated with ESCOZUL show a pain reduction.
Evaluation of the anti-inflammatory activity of the blue scorpion venom in experimental models of acute inflammation
he graphic shows the results of the acute anti-inflammatory experimental model. Three groups of laboratory mice subjected orally to different concentrations of ESCOZUL were examined, a group control (+) subjected to dexamet and a group control (-) without any anti-inflammatory. They were induced the inflammation by injecting croton oil into them and the effects were evaluated taken into account the mice's weight. The different letters inside the bars show significant statistical differences in weight between treatments, on the contrary, the treatments with equal letters show there are no differences between them. Thus, it can be seen that ESCOZUL has anti-inflammatory activity and that there are no differences between the effects of treatments with 5, 10 and 20 mg/Kg of ESCOZUL. The graphic shows the percentage of the inflammation inhibition for each treatment. It can be seen that the treatments with high concentrations of ESCOZUL can get to inhibit up to 38% of the inflammation. This experiment with mice could explain why cancer patients who are treated with ESCOZUL show a reduction in the appearance of edemas and inflammations.
Evaluation of the antiproliferative activity of ESCOZUL in cultures of tumor cell lines in vitro.
The graphic shows the percentage of cell growth of different cell cultures when treated with dissimilate doses of ESCOZUL. It can be observed that ESCOZUL has antiproliferative activity and the more concentrated the dose, the lower the cell proliferation will be. The greater reduction was obtained for the lung and larynx cell lines.
Evaluation of the antitumoral activity in murine tumors in vivo
The following graphic shows the behavior of the tumor growth in four experimental groups subjected to different doses of ESCOZUL. It can be seen that ESCOZUL has antitumoral activity and the more concentrated the dose, the more slowly the tumor will grow. The results in experimental models with implanted tumors in vivo evidence that the venom is able to significantly reduce the tumor progression and is more effective in lung cancer.
+So, how does ESCOZUL work? No one has a clear idea of ESCOZUL's anticarcinogenic mechanism. There are many theories about a possible action through: an inmune-modulator effect, angiogenesis inhibitor or an apoptosis potentiator. Cuban researchers explain that ESCOZUL firstly surrounds cancer with proteins that stop its progression. This first action does not allow cancer to spread. Secondly, ESCOZUL inhibits the growth of blood vessels around cancer. This last action as an inhibitor of angiogenesis causes the death of tumor cells since they can not live without the nutrients carried by the blood. Of course, if the cancer is very spread it is more difficult to surround and kill the tumor cells. It is for this reason that researchers say ESCOZUL works better when it is used during the early stages of the disease, but as it has been said before cancer patients with terminal prognosis have survived for more than 4 years taking ESCOZUL!
Biochemical characterization of the venom of the blue scorpion Rhopalurus junceus
This research is still under way and the results are kept secret. The objective of this research is to identify the active principle of the blue scorpion venom in order to obtain its synthesis at a later stage. As far as we know, the active principle is composed of peptides instead of large proteins.